$is_valid_institution:
$is_valid_institution_group_access: no
$valid_institution_id:

Economic cost of delayed access to 14 new cancer medicines in Canada’s public drug plans.

Download Full Article Article Brief

Summary

Author: Nigel SB Rawson, Ph.D.

The aim of this analysis is to estimate the number of potential patients impacted by provincial drug insurance coverage delays for a number of selected oncology drugs approved between 2010 and 2013 and the associated economic cost of these delays.

Revisions: This paper was revised to reflect additional information as of August 24, 2016.

Subscribe image

CHP blogazine

Opinions


Warning: Unknown: Your script possibly relies on a session side-effect which existed until PHP 4.2.3. Please be advised that the session extension does not consider global variables as a source of data, unless register_globals is enabled. You can disable this functionality and this warning by setting session.bug_compat_42 or session.bug_compat_warn to off, respectively. in Unknown on line 0